Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

CONCLUSION: Clinicians will frequently agree with patient-reported symptoms and performance status, and will use this information to guide documentation and symptom management. (ClinicalTrials.gov: NCT00807573). PMID: 26542025 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26542025?dopt=Abstract

Source: Clinical Trials - November 4, 2015 Category: Research Authors: Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC Tags: Clin Trials Source Type: research